AU2001270304A1 - Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor - Google Patents

Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor

Info

Publication number
AU2001270304A1
AU2001270304A1 AU2001270304A AU7030401A AU2001270304A1 AU 2001270304 A1 AU2001270304 A1 AU 2001270304A1 AU 2001270304 A AU2001270304 A AU 2001270304A AU 7030401 A AU7030401 A AU 7030401A AU 2001270304 A1 AU2001270304 A1 AU 2001270304A1
Authority
AU
Australia
Prior art keywords
protection
methods
squamous epithelium
novel agents
noxious substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270304A
Inventor
Richard A. Hudson
Roy C. Orlando
Liyanaaratchinge M. V. Tillekeratne
Neila A. Tobey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
University of Toledo
Original Assignee
Tulane University
University of Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University, University of Toledo filed Critical Tulane University
Publication of AU2001270304A1 publication Critical patent/AU2001270304A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/02—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C305/04—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to acyclic carbon atoms of a carbon skeleton being acyclic and saturated
    • C07C305/10—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to acyclic carbon atoms of a carbon skeleton being acyclic and saturated being further substituted by singly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001270304A 2000-07-07 2001-07-05 Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor Abandoned AU2001270304A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21677100P 2000-07-07 2000-07-07
US60216771 2000-07-07
PCT/US2001/021328 WO2002004411A1 (en) 2000-07-07 2001-07-05 Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor

Publications (1)

Publication Number Publication Date
AU2001270304A1 true AU2001270304A1 (en) 2002-01-21

Family

ID=22808444

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270304A Abandoned AU2001270304A1 (en) 2000-07-07 2001-07-05 Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor

Country Status (5)

Country Link
US (1) US6743820B2 (en)
AR (1) AR029569A1 (en)
AU (1) AU2001270304A1 (en)
PE (1) PE20020262A1 (en)
WO (1) WO2002004411A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138851A2 (en) * 2009-05-29 2010-12-02 The University Of North Carolina At Chapel Hill E-cadherin as a biomarker of gastroesophageal reflux disease
CN103787936B (en) * 2014-01-20 2016-06-08 新发药业有限公司 A kind of industrialized production is with the trans simple synthesis to first sulfydryl cinnamyl alcohol

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608061A (en) 1968-08-21 1971-09-21 Edmund F Mcnally Radiopaque esophageal marshmallow bolus
US4328244A (en) 1980-05-21 1982-05-04 The Dow Chemical Company Novel (((substituted-phenyl)methyl)amino)benzenesulfonic acids and pharmaceutically-acceptable salts thereof
FR2500825B1 (en) 1981-02-27 1985-08-23 Torii & Co Ltd NOVEL SUBSTITUTED 4-AMIDINO-PHENYL CARBOXYLATE, PREPARATION METHOD THEREOF AND ANTI-COMPLEMENT AGENT COMPRISING SAME
DE3323702A1 (en) * 1983-07-01 1985-01-10 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin 5-AMINOSALICYL ACID-O-SULFATES OF PHYSIOLOGICALLY POSSIBLE BASES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM
US5087638A (en) 1984-06-20 1992-02-11 Merck Frosst Canada, Inc. Benzofuran derivatives
DK164199C (en) 1986-05-16 1992-10-19 Chugai Pharmaceutical Co Ltd SUCRALPHATE PREPARATION FOR USE ON OESOPHAGUS MUCOSA
US5141855A (en) 1986-07-28 1992-08-25 Eastman Kodak Company Signal amplifying cobalt (III) redox reagents and methods for the determination of analytes in aqueous fluids
JPS63233968A (en) * 1987-03-23 1988-09-29 Yamanouchi Pharmaceut Co Ltd 2-hexaprehnylhydroquinonesulfate and medicine consisting of said compound
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
US5011846A (en) 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US4975281A (en) 1989-01-30 1990-12-04 E. R. Squibb & Sons, Inc. Anti-ulcer composition
US5206427A (en) 1989-09-16 1993-04-27 Bayer Aktiengesellschaft Process for the preparation of aromatic (di)chlorosulphonic acids and (di)bromosulphonic acids
US5189056A (en) * 1989-12-19 1993-02-23 University Of North Carolina At Chapel Hill Protection of moist stratified squamous epithelia against damage from noxious luminal agents
US5753631A (en) 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US5955470A (en) 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
GB9225475D0 (en) 1992-12-05 1993-01-27 Imp Cancer Res Tech Compounds to combat angiogenesis
US5670163A (en) 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
SE9402431D0 (en) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
IL117438A (en) 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US5495851A (en) 1995-03-23 1996-03-05 Roanoke Gastroenterology, P.C. Use of endoscopic ultrasound and stimulated bilary drainage in the diagnosis of cholecystitis and microlithiasis
CA2219603C (en) 1996-10-31 2002-06-18 The Procter & Gamble Company Method of stimulating gastrointestinal motility with ellagic acid
CA2219605C (en) 1996-10-31 2002-02-05 Deepa Ashok Khambe Method of stimulating gastrointestinal motility with ellagic acid
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
BR9811678A (en) 1997-07-10 2000-09-19 Janssen Pharmaceutica Nv 6-azauracil derivatives inhibiting il-5
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
RS50104B (en) 1998-08-21 2009-01-22 Novartis Ag., New oral formulation for 5-th4 agonists or antagonists

Also Published As

Publication number Publication date
PE20020262A1 (en) 2002-04-08
US6743820B2 (en) 2004-06-01
AR029569A1 (en) 2003-07-02
US20020052408A1 (en) 2002-05-02
WO2002004411A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
AU5274000A (en) Prevention of regression in refractive keratoplasty
ID30322A (en) HETEROSICLIC CONTAINING aP2 BIFENIL INHIBITOR AND ITS METHODS
AU2111199A (en) Benzenesulfonamides and benzamides as therapeutic agents
AU2001277754A1 (en) Proline derivatives and use thereof as drugs
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2001253065A1 (en) Compositions and methods for treating hair loss using oximyl- and hydroxylamino-prostaglandins
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2206699A (en) Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU750934C (en) Use of emulsions as impregnating agents and reviving agents
ZA982157B (en) Substituted amino compounds and their use as substances having an analgesic effect
AU4136200A (en) Trigger safety
AU2002213466A1 (en) Compounds and methods for modulating ccr4 function
AU2735995A (en) Hydroxylamine derivatives and their use as metalloproteinase inhibiting agents
AU2001273052A1 (en) Antifungal compounds and methods of use
AU2405001A (en) Worldwide early warning network and method of use
AU2001270304A1 (en) Methods for protection of stratified squamous epithelium against injury by noxious substances and novel agents for use therefor
AU6714996A (en) 2-(fluorenonyl)-carbapenems, compositions and methods of use
AU2962400A (en) Cleaner composition and method of use thereof
AU2001288291A1 (en) Paving and sealing composition and method of use
AU3725500A (en) Hand-held bidet and method of use
AU2001280847A1 (en) Assay methods for identifying compounds which may protect stratified squamous epithelium against damage by noxious substances
AU2676100A (en) Composition comprising an oil-in-water emulsion and an inorganic agent
AU3863900A (en) Prolyl peptidases and methods of use
AU6293200A (en) Cosmetic composition for moisturizing and protecting elastine fibers
AU4308699A (en) Use of anti-prolactin agents to treat proliferative conditions